Indian deal values reached $36.3 billion in Q2 2026, marking a 127% quarterly increase despite an 18% decline in the number of transactions. Large outbound acquisitions, headlined by Sun Pharma's $11.8 billion purchase, drove this growth to a four-year high. While M&A activity surged, private equity investments saw a moderate dip in both volume and total value.
The Indian dealmaking environment witnessed a significant shift in the second quarter of 2026, characterized by fewer transactions but substantially higher deal values. Total deal value reached $36.3 billion, a 127% increase over the previous quarter, according to data from Grant Thornton Bharat. This trend indicates a preference for large-scale strategic consolidation over smaller, high-frequency deal activity.
Pharma Leads with Record Outbound Acquisitions
The pharmaceutical, healthcare, and biotech sector emerged as the clear leader, contributing $13.7 billion to the total deal value. This dominance was largely due to Sun Pharmaceutical Industries’ acquisition of Organon & Co. for $11.8 billion. This deal stands as a landmark, representing the largest overseas acquisition ever undertaken by an Indian pharmaceutical company. By acquiring Organon, Sun Pharma aims to expand its footprint in international markets and diversify its product portfolio, though investors will likely focus on the company's ability to integrate these global operations and manage the associated debt impact.
M&A Dominance and Private Equity Trends
Mergers and acquisitions (M&A) were the primary drivers of this growth, totaling $27.9 billion across 240 deals. Outbound transactions, where Indian companies acquire businesses abroad, accounted for 84% of this M&A value. This surge marks the highest quarterly M&A value recorded since Q2 2022. While these large acquisitions signal corporate confidence, they often involve significant capital spending, which can impact cash flow and balance sheets in the short term.
In contrast, private equity (PE) activity faced a cooling period. PE investments totaled $8.4 billion across 325 deals, reflecting an 8% decline in value and a 22% drop in volume compared to the first quarter of 2026. Despite the overall slowdown, the trend towards larger average deal sizes continues. Notably, new companies such as Skyroot Aerospace, Square Yards Consulting, Sarvam AI, and KreditBee entered the unicorn club, suggesting that investors remain selective but willing to deploy capital into high-growth, technology-driven sectors. Additionally, the $1.6 billion acquisition of the Rajasthan Royals IPL franchise highlighted continued interest in high-value sports and entertainment assets.
Capital Raising and Sector Performance
Public market fundraising patterns remained varied during the quarter. IPO activity experienced a slight softening with 11 companies raising $1.1 billion. Conversely, companies increasingly turned to Qualified Institutional Placements (QIPs) to raise capital, with 16 issuances totaling $2.3 billion. Beyond the dominant pharma sector, manufacturing remained a strong contributor with $3.5 billion in deals, while the retail, consumer, and IT sectors led in the total number of transactions. As the market moves into the next quarter, investors will likely track whether this trend of large-value outbound acquisitions continues and how companies manage the integration of these massive global assets.